Go Pro

ChronoScale Corporation Common Stock (NASDAQ:CHRN) Trading 6.6% Higher - Time to Buy?

ChronoScale Corporation Common Stock logo with Technology background
Image from MarketBeat Media, LLC.

Key Points

  • CHRN rose 6.6% to $18.83, although trading volume was 84% below its average session volume.
  • Analyst sentiment remains negative: the stock has a consensus rating of “Reduce” and a $6.00 target price, versus its recent trading price near $18.83.
  • The company reported a quarterly loss of $0.12 per share on $18.4 million in revenue, with a negative net margin of 135.66% and negative return on equity of 197.81%.
  • MarketBeat previews top five stocks to own in October.

ChronoScale Corporation Common Stock (NASDAQ:CHRN - Get Free Report)'s stock price was up 6.6% during trading on Wednesday . The stock traded as high as $18.87 and last traded at $18.83. Approximately 39,104 shares were traded during trading, a decline of 84% from the average session volume of 243,492 shares. The stock had previously closed at $17.66.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded ChronoScale Corporation Common Stock from a "sell (d-)" rating to a "sell (d)" rating in a research report on Monday, August 24th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Reduce" and a consensus target price of $6.00.

View Our Latest Report on CHRN

ChronoScale Corporation Common Stock Stock Up 6.9%

The company has a market capitalization of $2.75 billion, a price-to-earnings ratio of -3.51 and a beta of 1.00. The company has a quick ratio of 0.51, a current ratio of 0.51 and a debt-to-equity ratio of 0.06. The business has a 50-day moving average price of $21.60 and a 200-day moving average price of $16.31.

ChronoScale Corporation Common Stock (NASDAQ:CHRN - Get Free Report) last released its quarterly earnings results on Wednesday, August 19th. The company reported ($0.12) earnings per share for the quarter. The company had revenue of $18.40 million during the quarter. ChronoScale Corporation Common Stock had a negative net margin of 135.66% and a negative return on equity of 197.81%. As a group, equities analysts anticipate that ChronoScale Corporation Common Stock will post -0.1 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Virtu Financial LLC purchased a new stake in ChronoScale Corporation Common Stock in the 3rd quarter worth about $57,000. Citadel Advisors LLC purchased a new position in ChronoScale Corporation Common Stock during the 3rd quarter valued at about $198,000. Geode Capital Management LLC grew its stake in ChronoScale Corporation Common Stock by 68.9% during the 4th quarter. Geode Capital Management LLC now owns 25,212 shares of the company's stock valued at $218,000 after acquiring an additional 10,281 shares in the last quarter. Shay Capital LLC acquired a new position in shares of ChronoScale Corporation Common Stock in the 3rd quarter valued at about $67,000. Finally, Roble Belko & Company Inc increased its holdings in shares of ChronoScale Corporation Common Stock by 104.5% in the 1st quarter. Roble Belko & Company Inc now owns 2,338 shares of the company's stock valued at $25,000 after purchasing an additional 1,195 shares during the period. Hedge funds and other institutional investors own 6.42% of the company's stock.

About ChronoScale Corporation Common Stock

(Get Free Report)

Ekso Bionics Holdings, Inc NASDAQ: EKSO is a leading developer of wearable bionic exoskeletons designed to enhance human mobility and strength. Headquartered in Richmond, California, the company was founded in 2005 (originally as Berkeley Bionics) and completed its initial public offering in 2014. Its patented robotic systems support both rehabilitation and industrial applications by providing powered, adjustable assistance for a range of movement tasks.

In the medical sector, Ekso Bionics offers externally worn exoskeletons such as the EksoNR and EksoGT, which assist patients recovering from stroke, spinal cord injury or other neurological conditions.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Should You Invest $1,000 in ChronoScale Corporation Common Stock Right Now?

Before you consider ChronoScale Corporation Common Stock, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ChronoScale Corporation Common Stock wasn't on the list.

While ChronoScale Corporation Common Stock currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own - Summer 2026 Cover

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines